PATHOGENETIC ASPECTS OF THE DEVELOPMENT OF CHANGES IN THE CARDIOVASCULAR SYSTEM IN PATIENTS WITH COVID-19 AGAINST TYPE II DIABETES
DOI:
https://doi.org/10.11603/1811-2471.2024.v.i1.14492Keywords:
COVID-19, diabetes, cardiovascular pathology, electrocardiogramAbstract
The relevance of the chosen topic is beyond doubt, since the incidence of diabetes and cardiovascular pathology occupy the leading places in the structure of morbidity in Ukraine and in the world, and the COVID-19 pandemic has worsened the prognosis for such patients. The purpose of our work was to analyze the domestic and foreign experience in studying the mutual effects of changes that occur in the cardiovascular system in type 2 diabetes with of COVID-19, as well as to analyze the results of the electrocardiogram of hospitalized patients with respiratory syndromes caused by SARS-CoV-2 in comorbidities with pathology of the cardiovascular system and type 2 diabetes.
Materials and methods. The literature review was performed using databases such as PubMed, Google Scholar, and real-time resources (eg, reports of the Ministry of Health of Ukraine, WHO). The medical histories of 39 patients with type 2 diabetes who were hospitalized for a complicated course of COVID-19 were analyzed. The analysis was performed in comparison with 14 patients who were hospitalized for a similar pathology, but did not suffer from diabetes.
The results. Patients with type 2 diabetes and cardiovascular disease have a higher susceptibility to complications when infected with SARS-CoV-2 than those who suffer from only one of these pathologies. The results of the ECG analysis in patients with type 2 diabetes revealed blockade of one of the legs of the bundle of His, sinus bradycardia and extrasystole twice as often as in patients without diabetes. Signs of ventricular hypertrophy (20.5% vs. 7.14%), diffuse changes in the myocardium, and heart attacks of various localization were registered in them three times more often, which was not the case in patients without type 2 diabetes. In general, the number of patients with a normal ECG in the experimental group was 30.81%, in the control group - 42.86%, despite the fact that the pathology of the cardiovascular system was also dominant in the control group.
Conclusions. Patients with diabetes mellitus, when infected with COVID-19, have a higher risk of developing cardiovascular changes, which are roughly reflected on the ECG and require a more detailed study of the functional state of the cardiovascular system using laboratory and instrumental diagnostic methods.
References
Gupta, A., Madhavan, M.V., Sehgal, K., Nair, N., Mahajan, S., & Sehrawat, T.S. (2020). Extrapulmonary manifestations of COVID-19. Nat. Med., 26, 1017-1032. DOI: 10. 1038/s41591-020-0968-3.
Siddiqi, H.K., & Mehra, M.R. (2020). COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J. Heart Lung Transplant. : Off. Publication Int. Soc. Heart Transplant, 39, 405-407. DOI: 10.1016/j.healun.2020.03.012.
Madjid, M., Safavi-Naeini, P., Solomon, S.D., & Vardeny, O. (2020). Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol., 5, 831-840. DOI: 10.1001/jamacardio.2020.1286.
Puntmann, V.O., Carerj, M.L., Wieters, I., Fahim, M., Arendt, C., & Hoffmann, J. (2020). Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol., 5, 1265. DOI: 10.1001/jamacardio.2020.3557.
Li, X., Guan, B., Su, T., Liu, W., Chen, M., & Bin Waleed, K. (2020). Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Heart, 106, 1142. DOI: 10.1136/heartjnl-2020-317062.
Wu, Z., & McGoogan, J.M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA, 323, 1239. DOI: 10.1001/jama. 2020.2648.
Chatrath, N., Kaza, N., Pabari, P. A., Fox, K., Mayet, J., & Barton, C. (2020). The effect of concomitant COVID-19 infection on outcomes in patients hospitalized with heart failure. ESC Heart Fail., 7, 4443-4447. DOI: 10.1002/ehf2.13059.
Einarson, T.R., Acs, A., Ludwig, C., & Panton, U.H. (2018). Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc. Diabetol., 17, 83. DOI: 10.1186/s12933-018-0728-6.
Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J.E. (2014). Global estimates of diabetes prevalence for 2013 and projections for 2035. Diab. Res. Clin. Practice, 103, 137-149. DOI: 10.1016/j.diabres.2013.11.002.
Piva, S. (2020). Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J. Crit. Care, 58, 29-33.
Myers, L.C., Parodi, S.M., Escobar, G.J. & Liu, V.X. (2020). Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA, 323, 2195-2198.
Szekely, Y., Lichter, Y., Taieb, P., Banai, A., Hochstadt, A., Merdler, I. (2020). Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study. Circulation, 142, 342-353. DOI: 10.1161/CIRCULATIONAHA. 120.047971.
Argulian, E., Sud, K., Vogel, B., Bohra, C., Garg, V.P., & Talebi, S. (2020). Right ventricular dilation in hospitalized patients with COVID-19 infection. JACC: Cardiovasc. Imag., 13, 2459-2461. DOI: 10.1016/j.jcmg.2020.05.010.
Teuwen, L.A., Geldhof, V., Pasut, A. & Carmeliet, P. (2020). COVID-19: the vasculature unleashed. Nat. Rev. Immunol., 20, 389-391.
Imai, Y. (2008). Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell, 133, 235-249.
Chen, I.Y., Moriyama, M., Chang, M.F. & Ichinohe, T. (2019). Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front. Microbiol., 10, 50.
Kuba, K., Imai, Y. & Penninger, J.M. (2006). Angiotensin-converting enzyme 2 in lung diseases. Curr. Opin. Pharmacol., 6, 271-276.
Huang, C. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395, 497-506.
Tang, X. (2020). Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. Chest, 158, 195-205.
Vaduganathan, M. (2020). Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N. Engl. J. Med., 382, 1653-1659.
Sestan, M. (2018). Virus-induced interferon-γ causes insulin resistance in skeletal muscle and derails glycemic control in obesity. Immunity, 49, 164177.e6.
Luther, J.M. & Brown, N.J. (2011). The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol. Sci., 32, 734-739.
Schwartz, S. S. (2016). The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema. Diabetes Care, 39, 179-186.
Teuwen, L.A., Geldhof, V., Pasut, A. & Carmeliet, P. (2020). COVID-19: the vasculature unleashed. Nat. Rev. Immunol., 20, 389-391.
Imai, Y. (2005). Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 436, 112-116.
Kuba, K. (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med., 11, 875-879.
Hebbard, C., Lee, B., Katare, R., & Garikipati, V.N.S. (2021). Diabetes, heart failure, and COVID-19: An update. Front. Physiology, 12, 706185. DOI: 10.3389/fphys.2021. 706185.
Retrieved from: https://www.medscape.com/viewarticle/picture-covid-19-europe-complex-2024a10001qs?ecd=WNL_trdalrt_pos1_240124_etid6264827&uac=425126HR&impID=6264827.
Zhou, F. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395, 1054-1062.
Chen, G. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest., 130, 2620-2629.
Marwick, T.H. (2008). Diabetic heart disease. Postgraduate Med. J., 84, 188-192. DOI: 10.1136/hrt.2005. 067231.
Lew, J.K.S., Pearson, J.T., Schwenke, D.O., & Katare, R. (2017). Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways. Cardiovasc. Diabetol., 16, 10. DOI: 10.1186/s12933-016-0484-4.
Freaney, P.M., Shah, S.J., & Khan, S.S. (2020). COVID-19 and heart failure with preserved ejection fraction. JAMA, 324, 1499-1500. DOI: 10.1001/jama.2020.17445.
Li, B., Yang, J., Zhao, F., Zhi, L., Wang, X., & Liu, L. (2020). Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol., 109, 531-538. DOI: 10.1007/s00392-020-01626-9.
Barron, E., Bakhai, C., Kar, P., Weaver, A., Bradley, D., & Ismail, H. (2020). Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diab. Endocrinol., 8, 813-822. DOI: 10.1016/S2213-8587(20)30272-2.
Abe, T., Egbuche, O., Igwe, J., Jegede, O., Wagle, B., & Olanipekun, T. (2021). Cardiovascular complications in COVID-19 patients with or without diabetes mellitus. Endocrinol. Diab. Metab., 4, e00218. DOI: 10.1002/edm2.218.
Freaney, P.M., Shah, S.J., & Khan, S.S. (2020). COVID-19 and heart failure with preserved ejection fraction. JAMA, 324, 1499-1500. DOI: 10.1001/jama.2020.17445.
